As of Aug 26
| -0.03 / -0.63%|
The 5 analysts offering 12-month price forecasts for Merrimack Pharmaceuticals Inc have a median target of 13.00, with a high estimate of 15.00 and a low estimate of 7.00. The median estimate represents a +174.26% increase from the last price of 4.74.
The current consensus among 6 polled investment analysts is to Buy stock in Merrimack Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.